|
Anemia Drugs Risky in Renal Failure Patients - CalorieLab Calorie Counter News |
CalorieLab Calorie Counter News
FDA officials are warning that the drugs Procrit, Aranesp and Epogen, all developed by Amgen Inc., that treat anemia by stimulating red blood cell production should be given at lower than normal doses in patients with kidney failure.
|
|
ERA: Bardoxolone Methyl May Increase eGFR in CKD - Doctors Lounge |
Doctors Lounge
... published online June 24 in the New England Journal of Medicine, to coincide with its presentation at the 48th European Renal Association -- European Dialysis and Transplant Association Congress, held from June 23 to 26 in Prague, Czech Republic.
|
FDA Urges Less Use of Anemia Drugs - New York Times |
New York Times
“It's going to hit the dialysis population right now in a big way.” The medicines have cost the federal government more than $60 billion since they were introduced in 1989, and for years they were the biggest single drug expense in the federal Medicare
|
FDA: New Warning for Procrit, Epogen, Aranesp - WebMD |
WebMD
The advice is different for CKD patients on dialysis and for CKD patients not on dialysis. Begin ESA treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or reaches 11 g/dL, reduce the ESA dose or suspend ...
FDA places dose limits on anemia drugs Cardiovascular Business
New Dosing Guidelines for Erythropoiesis-Stimulating Agents Medscape
Breaking news: FDA calls for changes in ESA dosing for patients with chronic
|
Vehicle stolen from dialysis patient's driveway - The Columbian |
The Columbian
A woman heading to her car to drive to a kidney dialysis appointment opened the door to her driveway early Friday morning to find the vehicle missing. “I figure it's long gone,” Theresa Ford, 57, said of her 1996 black Honda Accord.
|
|
|
|
<< Start < Prev 831 832 833 834 835 836 837 838 839 840 Next > End >>
|
Page 836 of 2630 |